Consistently, Thioredoxin-2 overexpression reduces mitochondrial oxidative stress and apoptosis while inhibiting VEGF-B signaling prevents the development of NAFLD by targeting lipolysis in white adipose tissue [53]. This evidence concerns the gene VEGFB and metabolic dysfunction-associated steatotic liver disease.